Assessment methods of inhaled aerosols: Technical aspects and applications

Expert Opinion on Drug Delivery

Volumn 6, Issue 9, 2009, Pages 941-959

  Jaafar Maalej, Chiraz ^a   Andrieu, Véronique ^b   Elaissari, Abdelhamid ^a   Fessi, Hatem ^a  

^a UNIVERSITÉ LYON 1   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Aerosol; Assessment methods; Drug delivery; Gamma camera; Impactor; Lung; Mass median aerodynamic diameter; Mathematical simulation; Pharmacological methods; Pulmonary

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SALBUTAMOL; TOBRAMYCIN; TRIAMCINOLONE ACETONIDE; ZANAMIVIR;

AEROSOL; AREA UNDER THE CURVE; ASTHMA; BIOEQUIVALENCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; GASTROINTESTINAL ABSORPTION; HUMAN; INHALATION SPACER; LASER DIFFRACTION; LOWER RESPIRATORY TRACT; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; PARTICLE SIZE; PHARMACOPHORE; POSITRON EMISSION TOMOGRAPHY; RESPIRATORY EPITHELIUM; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT;

EID: 70249097046     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903117244     Document Type: Review

References (109)

1. Frijlink H, De-Boer H. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004;1(1):67-86 (Pubitemid 40297957)
2. Newhouse M, Corkery K. Aerosols for systemic delivery of macromolecules. Respir Care Clin N Am 2001;7(2):261-275
3. Karathanasis E, Ayyagaric A, Bhavane R, et al. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. J Control Release 2005;103(1-2):159-175 (Pubitemid 40248570)
4. Trammer B, Amann A, Haltner-Ukomadu E. Comparative permeability and diffusion kinetics of cyclosporine: a liposomes and propylene glycol solution from human lung tissue into human blood ex vivo. Eur J Pharm Biopharm 2008;70(3):758-764
5. Stark B, Andreae F, Mosgoeller W. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation. Eur J Pharm Biopharm 2008;70(1):153-164
6. Elversson J, Millqvist-Fureby A, Alderborn G, et al. Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray-drying. J Pharm Sci 2003;92(4):900-910 (Pubitemid 36397005)
7. Bosquillon C, Rouxhet P, Ahimou F. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Control Release 2004;99(3):357-367 (Pubitemid 39296905)
8. Sbirlea-Apiou G, Katz I, Caillibotte G, et al. Inhalation aerosols: physical and biological basis for therapy. Hickey AJ: Informa healthcare, 2006
9. Kusmartseva O, Kattige A, Price R, et al. In-line assessment of pulmonary drug delivery using light obscuration. Biosens Bioelectron 2004;20(3):468-474 (Pubitemid 39445757)
10. Levitzky M. Pulmonary Physiology. McGraw-Hill Medical Publishing Division, New York, USA. 2003
11. Gunasekara L, Schürch S, Schoel W. Pulmonary surfactant function is abolished by an elevated proportion of cholesterol. Biochim Biophys Acta: Mol Cell Biol Lipids 2005;1737(1):27-35 (Pubitemid 41550380)
12. Forbes B. Human airway epithelial cell lines for in vitro drug transport and metabolism studies. Pharm Sci Technol Today 2000;3(1):18-27 (Pubitemid 30066491)
13. Chang M, Shih L, Wu R. The Pulmonary Epithelium in Health and Disease. David Proud: Wiley, UK. 2008
14. Florea B, Cassara M, Junginger H, et al. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release 2003;87(1-3):131-138 (Pubitemid 36255450)
15. Finlay W. Pharmaceutical inhalation aerosol technology. Hickey AJ: Marcel Dekker, New York, USA. 2003
16. Wright J. Pulmonary surfactant: a front line of lung host defense. J Clin Invest 2003;111(10):1453-1455 (Pubitemid 38063275)
17. Phillips J, Hey J, Corboz M. Computer assisted measurement of airway gland secretions by the hillocks technique. Comput Methods Programs Biomed 2002;68(3):215-222 (Pubitemid 34628909)
18. Rubin B. Physiology of airway mucus clearance. Respir Care 2002;47(7):761-768
19. King M. Physiology of mucus clearance. Paediatr Respir Rev 2006;7(1):S212-4
20. Samet J, Cheng P. The role of airway mucus in pulmonary toxicology. Environ Health Perspect 1994;102(2):89-103 (Pubitemid 24217798)
21. Edsbäckera S, Wollmerb P, Selroosc O, et al. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?. Pulm Pharmacol Ther 2008;21(2):247-258
22. Wang L, Scabilloni J, Antonini J. Role of lung surfactant in phagocytic clearance of apoptotic cells by macrophages in rats. Lab Invest 2006;86(5):458-466
23. Jain D, Dodia C, Fisher A, et al. Pathways for clearance of surfactant protein A from the lung. Am J Physiol Lung Cell Mol Physiol 2005;289(6):L1011-8 (Pubitemid 41681336)
24. Wang J, Reid K. The immunoregulatory roles of lung surfactant collectins SP-A, and SP-D, in allergen-induced airway inflammation. Immunobiology 2007;212(4):417-425 (Pubitemid 46825243)
25. Leonenko Z, Finot E, Vassiliev V, et al. Effect of cholesterol on the physical properties of pulmonary surfactant films:atomic force measurements study. Ultramicroscopy 2006;106(8):687-694 (Pubitemid 43994313)
26. McCrae K, Rand T, Shaw R. Analysis of pulmonary surfactant by Fourier-transform infrared spectroscopy following exposure to Stachybotrys chartarum (atra) spores. Chem Phys Lipids 2001;110(1):1-10 (Pubitemid 32197583)
27. Foot N, Orgeig S, Daniels C. The evolution of a physiological system: the pulmonary surfactant system in diving mammals. Respir Physiol Neurobiol 2006;154(1):118-138 (Pubitemid 44666581)
28. Fehrenbach H. Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2001;2(1):33-46 (Pubitemid 34187905)
29. Biddiscombe M, Usmani O, Barnes P. A system for the production and delivery of monodisperse salbutamol aerosols to the lungs. Int J Pharm 2003;254(2):243-253 (Pubitemid 36298833)
30. Scheuch G, Siekmeier R. Novel approaches to enhance pulmonary delivery of proteins and peptides. J Physiol Pharmacol 2007;58(5):615-625 (Pubitemid 351346710)
31. Scheuch G, Kohlhaeufl M, Brand P, et al. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006;58(9-10):996-1008 (Pubitemid 44709266)
32. Groneberg D, Paul H, Welte T. Novel strategies of aerosolic pharmacotherapy. Exp Toxicol Pathol 2006;57(2):49-53
33. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 2004;1(4):315-320
34. Khilnani G, Banga A. Aerosol therapy. Indian J Chest Dis Allied Sci 2008;50(2):209-219
35. Groneberge DA, Witt C, Wagner U, et al. Fundamentals of pulmonary drug delivery. Respir Med 2003;97(44):382-387 • Interesting review paper.
36. Labiris N, Dolovich M. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56(6):588-599 (Pubitemid 37491710)
37. Ma Z, Merkus H, Scarlett B. Extending laser diffraction for particle shape characterization: technical aspects and application. Powder Technol 2001;118(1-2):180-187 (Pubitemid 32707951)
38. Ma Z, Merkus H, De Smet J. New developments in particle characterization by laser diffraction: size and shape. Powder Technol 2000;111(1):66-78 (Pubitemid 30407160)
39. Mitchell J, Nagel M, Nichols S, et al. Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers. J Aerosol Med 2006;19(4):409-433 •• Papers of considerable interest about aerosol characterisation methods. (Pubitemid 46067762)
40. Haynes A, Shaik A, Krarup H, et al. Evaluation of the malvern spraytec with inhalation cell for the measurement of particle size distribution from metered dose inhalers. J Pharm Sci 2004;93(2):349-363 (Pubitemid 38174257)
41. Waldrep JC, Berlinski A, Dhand R. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer. J Aerosol Med 2007;20(3):310-319 (Pubitemid 47463184)
42. De-Boer A, Gjaltema D, Hagedoorn P, et al. Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols. Int J Pharm 2002;249(1-2):233-245 (Pubitemid 35333449)
43. Mitchell J, Nagel M. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med 2003;16(4):341-377 •• Papers of considerable interest about aerosol characterisation methods. (Pubitemid 38120942)
44. Sethuraman V, Hickey A. Evaluation of preseparator performance for the 8-stage nonviable andersen impactor. AAPS PharmSciTech 2001;2(1):1-19 (Pubitemid 41086056)
45. Kim M, Kim D, Lee K. Multijet and multistage aerosol concentrator: design and performance analysis. J Aerosol Med 2001;14(2):245-254 (Pubitemid 32744356)
46. EP 6.0. Preparations for inhalation: aerodynamic assessment of fine particles. Europeen Pharamacopeia 6.0, 2008
47. USP 26-NF21. Physical tests and determinations: aerosols. United states Pharmacopeia: Rockville MD, 2003
48. Marple VA, Rubow KL. Generation of Aerosols and Facilities for Exposure Experiments, Chapter 1: Aerosol Generation Concepts and Parameters, Ed K. Willeke, Ann Arbor Science Publishers, Inc. Ann Arbor, MI, 1980
49. Hering S, Flagan R, Friedlander S. Design and evaluation of a new low-pressure impactor. Environ Sci Technol 1978;12(6):667-673 (Pubitemid 8603512)
50. Newman S, Wilding I, Hirst P. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products?. Int J Pharm 2000;208(1-2):49-60 (Pubitemid 30813346)
51. Newman S, Pitcairn G. In vitro/in vivo correlations for respiratory drug delivery. Clin Res Regul Aff 2005;22(1):15-30
52. Marple V, Roberts D, Romay F. Next generation pharmaceutical impactor (A new impactor for pharmaceutical inhaler testing) /Part 1. Design. J Aerosol Med 2003;16(3):283-299 (Pubitemid 37169639)
53. Hoe S, Young P, Chan H, et al. Introduction of the electrical next generation impactor (eNGI) and investigation of its capabilities for the study of pressurized metered dose inhalers. Pharm Res 2009;26(2):431-437
54. Bonam M, Christopher D, Cipolla D, et al. Minimizing variability of cascade impaction measurements in inhalers and nebulizers. AAPS PharmSciTech 2008;9(2):404-413
55. Stapleton K, Finlay W. Errors in characterizing particle size distributions with cascade impactors. J Aerosol Med 1998;11(1):S80-3 (Pubitemid 28286037)
56. Zhou Y, Ahuja A, Irvin C. Medical nebulizer performance: effects of cascade impactor temperature. Respir Care 2005;50(8):1077-1082 (Pubitemid 46179535)
57. Nerbrink OL, Pagels J, Pieron CA, et al. Effect of humidity on constant output and breath enhanced nebulizer designs when tested in the EN13544-1 EC Standard. Aerosol Sci Technol 2003;37(3):282-292 (Pubitemid 36222528)
58. Zhou Y, Ahuja A, Irvin C. Evaluation of nebulizer performance under various humidity conditions. J Aerosol Med 2005;18(3):283-293 (Pubitemid 41395730)
59. Solomita M, Smaldone G. Reconciliation of cascade impaction during wet nebulization. J Aerosol Med Pulm Drug Deliv 2009;22(1):1-8
60. Nasr M, Ross D, Miller N. Effect of drug load and plate coating on the particle size distribution of a commercial albuterol Metered Dose Inhaler (MDI) determined using the Andersen and Marple-Miller cascade impactors. Pharm Res 1997;14(10):1437-1443 (Pubitemid 27481076)
61. Mitchell J, Nagel M. Particle size analysis of aerosols from medicinal inhalers. KONA: Powder Particle 2004;22:32-65
62. Bosquillon C, Lombry C, Preat V, et al. Comparison of particle sizing techniques in the case of inhalation dry powders. J Pharm Sci 2001;90(12):2032-2041 (Pubitemid 33144449)
63. Schroeter J, Fleming J, Hwang D, et al. A computer model of lung morphology to analyze SPECT images. Comput Med Imaging Graph 2002;26(4):237-246 (Pubitemid 34628867)
64. Dolovich M, Labiris R. Imaging drug delivery and drug responses in the lung. Proc Am Thorac Soc 2004;1(4):329-337
65. Chan H. Encyclopedia of pharmaceutical technology. James Swarbrick: Marcel Dekker, New York, USA. 2002
66. Newman S, Pitcairn G, Hirst P, et al. Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv Drug Deliv Rev 2003;55(7):851-867 (Pubitemid 36776797)
67. Fleming J, Conway J. Three-dimensional imaging of aerosol deposition. J Aerosol Med 2001;14(2):147-153
68. Snell N, Ganderton D. Assessing lung deposition of inhaled medications-Consensus statement from a workshop of the British Association for Lung Research. Respir Med 1999;93(2):123-133
69. Dolovich M. Pharmaceutical inhalation aerosol technology. Hickey AJ: Marcel Dekker, New York, USA. 2004
70. Tafaghodi M, Sajadi-Tabassi S, Jaafari M. Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy. Int J Pharm 2004;280(1-2):125-135 (Pubitemid 38950910)
71. Möller W, Meyer G, Kreyling W. Advances in lung imaging techniques for the treatment of respiratory disease. Drug Discov Today: Ther Strateg 2008;5(2):87-92
72. Lee Z, Berridge M, Finlay W, et al. Mapping PET-measured triamcinolone acetonide (TAA) aerosol distribution into deposition by airway generation. Int J Pharm 2000;199(1):7-16 (Pubitemid 30224500)
73. Mobley C, Hochhaus G. Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today 2001;6(7):367-375 (Pubitemid 32208651)
74. Newman S. Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs? Br J Clin Pharmacol 2000;49(6):529-537
75. Newman S, Hirst P, Wilding I. New developments in radionuclide imaging for assessing drug delivery in man. Eur J Pharm Sci 2003;18(1):19-22 (Pubitemid 36120551)
76. Davies G, Nuermberger E. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis 2008;88(1):S65-74
77. Lipworth B. Pharmacokinectics of inhaled drugs. Br J Clin Pharmacol 1996;42(6):697-705
78. Girodet P, Molimard M. Pharmacological approach to evaluate aerosol pulmonary deposition. J Aerosol Med 2005;18(2):183-192 (Pubitemid 40911358)
79. Derendorf H, Nave R, Drollmann A. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28(5):1042-1050 (Pubitemid 46335529)
80. Chrystyn H. Methods to determine lung distribution of inhaled drugs-could gamma scintigraphy be the gold standard?. Br J Clin Pharmacol 2000;49(6):525-528 (Pubitemid 30326551)
81. Esposito-Festen J, Zanen P, Tiddens H, et al. Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. Br J Clin Pharmacol 2007;64(3):328-334 (Pubitemid 47283862)
82. Derendorf H, Hochhaus G, Möllmann H. Evaluation of pulmonary absorption using pharmacokinetic methods. J Aerosol Med 2000;14(1):9-17
83. Hirst P, Pitcairn G, Richards J. Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler. J Aerosol Med 2001;14(2):155-165 (Pubitemid 32744348)
84. Cass LM, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999;36(1):21-31 (Pubitemid 29322454)
85. Sebti T, Pilcer G, Van Gansbeke B, et al. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. Eur J Pharm Biopharm 2006;64(1):26-32 (Pubitemid 44142238)
86. Mitsakou C, Helmis C, Housiadas C. Eulerian modelling of lung deposition with sectional representation of aerosol dynamics. J Aerosol Sci 2005;36(1):75-94 (Pubitemid 39601425)
87. Asgharian B, Hofmann W, Bergmann R. Particle deposition in a multiple-path model of the human lung. Aerosol Sci Technol 2001;34(4):332-339 (Pubitemid 32246918)
88. Goo J, Kim C. Theoretical analysis of particle deposition in human lungs considering stochastic variations of airway morphology. J Aerosol Sci 2003;34(5):585-602 (Pubitemid 38352545)
89. International Commission on Radiological Protection Human respiratory tract model for radiological protection. A report of a task group of the International Commission on Radiological Protection. Ann ICRP 1994;24:1-120
90. Moskal A, Gradon L. Temporary and spatial deposition of aerosol particles in the upper human airways during breathing cycle. J Aerosol Sci 2002;33(11):1525-1539 (Pubitemid 35300481)
91. Sturm R, Hofmann W. Stochastic simulation of alveolar particle deposition in lungs affected by different types of emphysema. J Aerosol Med 2004;17(4):357-372 (Pubitemid 40116953)
92. Balásházy I, Alföldy B, Molnár A. Aerosol drug delivery optimization by computational methods for the characterization of total and regional deposition of therapeutic aerosols in the respiratory system. Curr Comput Aided Drug Des 2007;3(1):13-32 (Pubitemid 46403570)
93. Dunbar C, Scheuc G, Sommerer K. In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int J Pharm 2002;245(1-2):179-189
94. Fleming J, Epps B, Conway J, et al. Comparison of SPECT aerosol deposition data with a human respiratory tract model. J Aerosol Med 2006;19(3):268-278 (Pubitemid 44735385)
95. Zhang Y, Finlay W. Experimental measurements of particle deposition in three proximal lung bifurcation models with an idealized mouth-Throat. J Aerosol Med 2005;18(4):460-473 (Pubitemid 43038411)
96. Kamiya A, Sakagami M, Hindle M, et al. Aerodynamic sizing of metered dose inhalers: an evaluation of the andersen and next generation pharmaceutical impactors and their USP methods. J Pharm Sci 2004;93(7):1828-1837 •• Papers of considerable interest about aerosol characterisation methods. (Pubitemid 38823708)
97. Guo C, Gillespie S, Kauffman J, et al. Comparison of delivery characteristics from a combination metered-dose inhaler using the andersen cascade impactor and the next generation pharmaceutical impactor. J Pharm Sci 2008;97(8):3321-3334
98. Garmise R, Hickey A. Calibration of the andersen cascade impactor for the characterization of nasal products. J Pharm Sci 2008;97(8):3462-3466
99. Pilcer G, Vanderbist F, Amighi K. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations. Int J Pharm 2008;358(1-2):75-81
100. Marriott C, Macritchie H, Zeng X, et al. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations. Int J Pharm 2006;326(1-2):39-49 (Pubitemid 44649277)
101. Ziegler J, Wachtel H. Comparison of cascade impaction and laser diffraction for particle size distribution measurements. J Aerosol Med 2005;18(3):311-324 • Important comparative study. (Pubitemid 41395733)
102. Vecellio-None L, Grimbert D, Becquemin MH, et al. Validation of laser diffraction method as a substitute for cascade impaction in the European project for a nebulizer standard. J Aerosol Med 2001;14(1):107-114 (Pubitemid 32428975)
103. Kwong W, Ho S, Coates A. Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus andersen cascade impactor and low-flow Marple personal cascade impactor. J Aerosol Med 2000;13(4):303-314 (Pubitemid 32105616)
104. Agertoft L, Pedersen S. Lung deposition and systemic availability of fluticasone diskus and budesonide turbuhaler in children. Am J Respir Crit Care Med 2003;168(7):779-782 (Pubitemid 37188300)
105. Tomlinson H, Corlett S, Chrystyn H. Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. Br J Clin Pharmacol 2003;56(2):225-227 (Pubitemid 36981439)
106. Aswani O, Chrystyn H. Relative lung and systemic bioavailability of sodium cromoglycate inhaled products using urinary drug excretion post inhalation. Biopharm Drug Dispos 2002;23(4):159-163 (Pubitemid 34578275)
107. Anderson P, Zhou X, Breen P. Pharmacokinetics of (R, S)-Albuterol after aerosol inhalation in healthy adult volunteers. J Pharm Sci 2000;87(7):841-844 (Pubitemid 28319414)
108. Longest P, Xi J. Effectiveness of direct Lagrangian tracking models for simulating nanoparticle deposition in the upper airways. Aerosol Sci Technol 2007;41(4):380-397 (Pubitemid 46393082)
109. Longest P, Vinchurkar S, Martonen T. Transport and deposition of respiratory aerosols in models of childhood asthma. J Aerosol Sci 2006;37(10):1234-1257 (Pubitemid 44468215)